Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Pharmaceuticals, Inc. Chief Human Resources Officer Pamela J. Cramer reported equity compensation activity on February 1, 2026. She exercised restricted stock units into 13,293 shares of common stock and then had 4,731 shares of common stock withheld at $108.99 per share to cover tax obligations.
Following these transactions, she directly owned 29,376 shares of common stock. Several restricted stock unit awards continue to vest in 25% increments on specified dates from February 2026 through February 2029, each unit representing a right to receive one share of common stock.
The Vanguard Group has reported a significant institutional stake in Rhythm Pharmaceuticals. As of December 31, 2025, Vanguard beneficially owned 6,210,916 shares of Rhythm common stock, representing 9.3% of the outstanding class.
Vanguard reports no sole voting or dispositive power, with 490,294 shares subject to shared voting power and 6,210,916 shares subject to shared dispositive power. The holdings are for ordinary course investment purposes and are not intended to change or influence control of Rhythm. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries may report beneficial ownership separately.
Rhythm Pharmaceuticals reported estimated preliminary unaudited net product revenues from global sales of IMCIVREE of approximately $57 million for the fourth quarter of 2025, an 11% sequential increase from the third quarter of 2025. For full-year 2025, net product revenues are expected to be about $194 million, up from $130 million in 2024, an increase of roughly 50% year over year. U.S. sales accounted for about 68% of preliminary fourth quarter revenues and about 69% of preliminary full-year 2025 revenues.
The company highlighted upcoming milestones for setmelanotide, including a planned U.S. launch of IMCIVREE for acquired hypothalamic obesity pending FDA approval, with a PDUFA goal date of March 20, 2026, topline Phase 3 data in acquired HO and genetically caused MC4R pathway diseases in the first quarter of 2026, and additional Phase 2 data in Prader-Willi syndrome in the first half of 2026. Rhythm also plans a pivotal Phase 3 trial of bivamelagon in acquired HO and is advancing RM-718 in a Phase 1 trial. The company stressed that the financial figures are preliminary, unaudited estimates and may change after closing and audit procedures.
Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported an option exercise and share sale involving the company’s common stock.
On 12/11/2025, she exercised 3,350 stock options at $27.35 per share, acquiring 3,350 shares, and then sold 3,350 common shares at $111 per share under a Rule 10b5-1 trading plan adopted on August 7, 2025. Following these transactions, she directly held 20,814 common shares and 8,375 stock options expiring on 01/31/2033, which were granted on 02/01/2023 and vest in 16 substantially equal installments based on continued service.
Rhythm Pharmaceuticals (RYTM) reported an insider equity transaction by its Chief Human Resources Officer. On 11/20/2025, the officer exercised 3,350 stock options at an exercise price of $27.35 per share and acquired the same number of common shares. On the same date, 3,350 common shares were sold at a price of $105 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025.
After these transactions, the officer beneficially owned 20,814 shares of common stock directly and held 11,725 stock options that remain beneficially owned. The options exercised on November 20, 2025 were part of a grant made on February 1, 2023 that vests in 16 substantially equal quarterly installments, tied to continued service with the company.
Rhythm Pharmaceuticals (RYTM) insider activity: Chief Human Resources Officer Pamela J. Cramer reported option exercises and open‑market sales. On 11/07/2025, she exercised 8,805 options at $19.02 and 10,546 options at $6.80, then sold 19,351 shares at a weighted average price of $98.8231. On 11/10/2025, she exercised 3,515 options at $6.80 and sold 3,515 shares at $100.00.
Following these transactions, directly held common shares were 20,814. The sales were effected under a Rule 10b5‑1 trading plan adopted on August 7, 2025.
Derivative updates: post‑exercise, option holdings were 5,257 at a $19.02 strike (expires 07/25/2031) and 7,035 and 3,520 at a $6.80 strike (expire 02/08/2032). The filing notes one option grant is fully vested and another vests in 16 equal quarterly installments from February 9, 2022.
Rhythm Pharmaceuticals reported a regulatory timing update. The U.S. Food and Drug Administration extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity by three months, moving it from December 20, 2025 to March 20, 2026.
The company also furnished a press release and an investor presentation as exhibits to provide additional context. Information furnished under Regulation FD is not deemed filed for liability purposes.
Rhythm Pharmaceuticals (RYTM) filed its Q3 2025 10‑Q reporting higher sales and a narrower year‑to‑date loss. Q3 product revenue was $51.3 million, up from $33.3 million a year ago, reflecting continued uptake of IMCIVREE. The quarter’s net loss attributable to common stockholders was $54.3 million, or $0.82 per share.
For the nine months, revenue reached $132.5 million while the net loss narrowed to $149.0 million, helped by lower research and development expense ($125.3 million vs. $196.8 million in 2024) and higher selling, general and administrative expense supporting commercialization. Cash, cash equivalents and short‑term investments totaled $416.1 million as of September 30, 2025, with operating cash outflow of $90.3 million year‑to‑date. The company completed a public offering during the period, adding $188.7 million in net proceeds and also raised $34.0 million via an at‑the‑market program. Shares outstanding were 66,736,056 as of October 31, 2025.
Rhythm Pharmaceuticals, Inc. filed a current report stating that on November 4, 2025 it announced financial results for the third quarter ended September 30, 2025. The company released these results through a press release, which is provided as Exhibit 99.1.
The press release is being furnished, not filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Rhythm Pharmaceuticals (RYTM) Chief Technical Officer Joseph Shulman filed a Form 4 detailing an option exercise and same‑day sale on 10/30/2025. He exercised 9,748 stock options at $30.66 and then sold 9,748 common shares at a weighted average price of $115.2439.
The sales were executed in multiple trades between $115.00 and $115.73 and were made pursuant to a Rule 10b5‑1 plan adopted on August 8, 2024. Following these transactions, Shulman beneficially owns 8,509 shares directly. The reported stock option was fully vested prior to exercise and shows zero derivative securities remaining after the transaction.